A Note from Biosimilars Council Executive Director Christine Simmon
This month, the Biosimilars Council announced the release of AAM’s 2021 Generic Drug and Biosimilars Savings in the U.S. report. We are proud to note that biosimilars helped to cut the oncology spending growth rate nearly in half from 2019 to 2020. The report also finds biosimilars created $7.9 billion in savings in 2020, a three-fold increase over 2019. Overall, it shed light on many positive trends, and we look forward to seeing further growth for biosimilar medicines.
Indeed, opportunities to increase biosimilars utilization were highlighted in the Center for Medicare and Medicaid Innovation’s “strategic refresh” released this month, featuring the potential of a shared savings program – a Council advocacy priority – to drive greater patient uptake.
Looking ahead, we are excited for the GRx+Biosims 2021 conference taking place November 8-10, where we will discuss the positive news from the savings report and the future of biosimilar medicines in the United States. This year’s event will be held virtually. Don’t forget to register for this premier event here. To learn about sponsorship opportunities, please contact us through this form.
Last, the second annual Global Biosimilars Week, a globally aligned educational initiative to raise awareness for biosimilars worldwide, is happening now. Use the social toolkit to draft content and join the conversation on social media throughout this week to help us promote biosimilars.